Valneva Climbs 3.28% at Close Despite Challenges Since October
Valneva closed the trading session on Tuesday, November 11, 2025, at 3.84 euros, marking a 3.28% increase from the previous day. The vaccine specialist's stock now shows a remarkable annual performance of 59.15%, significantly outperforming the CAC 40's 11.14% over the same period. Despite this positive session, the recent context has been marked by turbulence, with a decline of 1.39% over the week and a moderate increase of 1.37% over three months.
Current Valuation and Market Dynamics
The current valuation of the stock, trading at 3.84 euros, remains significantly below its 50-day moving average of 4.19 euros, indicating persistent downward pressure since early October. On October 7, the company lowered its financial forecast for 2025, adjusting expected sales to between 155 and 170 million euros, down from 170 to 180 million euros previously, following the suspension by the US FDA of the license for its Ixchiq vaccine against chikungunya. This announcement led to a sharp drop in share price. The trading volume on November 11 accounted for 0.28% of the capital, indicating moderate liquidity in the stock. Technically, the RSI stands at 28, a level that signals a pronounced oversold zone and suggests a potential short-term rebound. This indicator, which measures the relative strength of the stock, indicates that the selling pressure of recent weeks could be waning. The MACD, another momentum indicator, shows a main line at -0.18 against a signal line at -0.15, with a negative histogram of -0.03, confirming a fundamental bearish trend that remains intact despite the session's rebound. The technical setup remains fragile, although oversold levels could favor tactical positioning.
Anticipation of Clinical Trial Results and Financial Moves
Investors are also awaiting the results of the Phase III clinical trial of the VLA15 vaccine against Lyme disease, now expected in the first half of 2026, a delay of several months from the initial schedule which anticipated results by the end of October 2025. This vaccine, co-developed with American giant Pfizer, is the main medium-term catalyst for the group. Valneva continues to target the submission of a marketing authorization application to US and European health authorities in 2026, with Pfizer planning to market this vaccine in the second half of 2027. Financially, the company has secured a refinancing of 500 million dollars from Pharmakon Advisors, including an initial tranche of 215 million dollars intended to fully repay its existing loan, pushing the repayment deadline to the fourth quarter of 2030.
Stock Price Resistance and Support Levels
The stock is currently trading between a support at 3.66 euros and a resistance at 5.09 euros, a range it must surpass to re-establish a sustainable upward trend. The 200-day moving average, set at 3.41 euros, remains a long-term support base, confirming that the stock maintains a valuation cushion despite recent difficulties. The Ixchiq vaccine, suspended by the FDA in August 2025, had generated a total of 7.5 million euros in sales in the first half of 2025, accounting for less than 8% of Valneva's total semi-annual revenue. While the financial impact of this suspension is limited proportionally, regulatory uncertainty weighs on investor sentiment. The rebound on November 11, driven by a 1.25% rise in the CAC 40, demonstrates the stock's resilience in a favorable market context, but the underlying trend remains conditioned on the clinical and regulatory progress of ongoing programs.
